CR O'Neil, JXQ Pang, SS Lee, et al. Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfectd patients are comparable with hepatitis C monoinfected patients. *Can J Infect Dis Med Microbiol* 2015;26(6):293-296.

To the Editor:

Hepatitis C virus (HCV) infection is an important cause of morbidity and mortality among individuals living with HIV (1). Before the introduction of direct-acting antivirals (DAAs), pegylated interferon (peg-IFN) and ribavirin (RBV) were standard of care for coinfectd patients with dismal sustained virological response (SVR) rates of <30% (2,3). Telaprevir (TVR), an NS3/4A protease inhibitor, was a first-generation DAA approved for HCV treatment in Canada, in November 2012. In randomized trials, the rate of SVR to TVR/peg-IFN/RBV was 65% to 75% in monoinfected patients and similar in coinfectd patients (4-8). Few studies have reported treatment outcomes of TVR-based therapy outside of clinical trials. Our objective was to compare clinical outcomes of HCV-monoinfected and HIV-HCV coinfectd patients treated with TVR-based triple therapy at a regional referral centre in Alberta.

Patients who initiated TVR/pegIFN/RBV combination therapy from June 2011 to December 2013, were included in the study. Patients were treated according to Canadian guidelines for HCV treatment (9,10). All patients with HCV genotype 1 were eligible for therapy and were treated at the discretion of their HCV care provider. Demographic, clinical and laboratory data were collected at baseline and during therapy. Parameters of interest included HIV-coinfection, body mass index (BMI), Child-Pugh classification, previous injection drug use, haemophilia, liver transplantation, hepatitis B coinfection and previous HCV treatment. Fibrosis was determined using transient elastography by FibroScan (Echosens, France) with the following parameters: F0 to F1 ≤ 7.0 , F2 7.1 to 9.4, F3 9.5 to 12.4, F4 (cirrhosis) ≥ 12.5 (11). Where applicable, HIV viral load and CD4⁺ T cell count were collected. Severe treatment-related anemia and thrombocytopenia were defined as nadir of hemoglobin ≤ 80 g/L and platelet count $\leq 50 \times 10^9$, respectively. Treatment response was determined using established definitions according to Canadian guidelines (9). Patients lost to follow-up were considered to have virological failure.

In total, 103 patients received TVR at our clinics (Table 1). This included 13 (12.6%) HIV-HCV coinfectd patients and seven (6.7%) patients who experienced recurrent HCV after liver transplantation. The median age at treatment onset was 56 years (interquartile range [IQR]: 51 to 59 years); 72% of patients were male and 86% were Caucasian. One-third (37%) of patients reported a history of injection drug use, nine (10%) had hemophilia and three (3%) were HCV-hepatitis B virus coinfectd. The median BMI was 26.8 kg/m² (IQR 24.0 kg/m² to 30.5 kg/m²). Forty-seven percent (n=45) of patients had been previously treated with pegIFN-RBV and 13% (n=12) were previous null responders. Most patients were HCV genotype 1a and IL28B non-CC genotype (71% and 70%, respectively). The majority (60%) of patients had advanced fibrosis or cirrhosis (F3 or F4). One patient had decompensated Child-Pugh B cirrhosis. HCV-HIV coinfectd patients did not differ significantly with respect to previous anti-HCV therapy, HCV genotype subtype, interleukin (IL)28B genotype or degree of fibrosis. Coinfectd patients were more likely to report injection drug use (P=0.05) and to have hemophilia (P=0.03). Most (92%) HIV coinfectd patients had undetectable HIV RNA while receiving antiretroviral therapy, with a median baseline CD4 count of 490 cells/mm³ (IQR 250 cells/mm³ to 639 cells/mm³). Most

(85%) required adjustment of their antiretroviral regimen before TVR initiation. Integrase-based antiretroviral therapy was the most commonly (77%) used regimen.

The overall rate of SVR in our cohort was 66% (Table 2). The rate of SVR among HIV-HCV coinfectd patients was 62% (eight of 13). Patients with cirrhosis and previous null responders had a lower SVR rate (54% and 42%, respectively). Fifty-seven percent (four of seven) of post-liver transplant recipients achieved SVR. Outcomes for post-liver transplant patients have been previously reported (12). Among treatment failures, discontinuation due to adverse events was the most common (20%), followed by virological relapse (15%). Five (5%) patients discontinued therapy due to hepatic decompensation. Two (2%) patients were lost to follow-up. Two (2%) patients died; one patient died due to drug and alcohol intoxication while on therapy. The other patient had Child-Pugh B cirrhosis at baseline and died from complications of decompensated cirrhosis. The most commonly reported side effects were fatigue (65%), rash (68%), mood symptoms (42%), anorectal symptoms (43%) and infections (17%). Severe anemia occurred in 15% of participants and warranted red blood cell transfusion or erythropoietin in 11% and 2%, respectively. Severe thrombocytopenia occurred in 24% of participants. Most (57%) patients required RBV dose reduction.

Comparing HCV monoinfected with HIV coinfectd patients, there was no significant difference with regard to SVR (67% versus 62%, P=0.76). There was no difference between monoinfected and coinfectd patients in treatment discontinuation due to adverse events (20% versus 15%; P=1.00) or virological relapse (13% versus 23%; P=0.40). One patient with HIV coinfection discontinued therapy due to hepatic decompensation, but nevertheless achieved SVR. There were no deaths among HIV-coinfectd patients. Patients with HIV coinfection were more likely to have infections (12% versus 48%; P $\leq$ 0.01), severe anemia (11% versus 38%; P=0.02) and to require peg-IFN dose adjustment (6% versus 46%; P $\leq$ 0.01). In HIV-coinfectd patients, infectious complications consisted of cellulitis (n=2), sepsis (n=1), gastroenteritis (n=1) and urinary tract infections (n=1). All HIV-coinfectd patients maintained undetectable HIV RNA while receiving therapy.

In a bivariate analysis, variables associated with increased rate of SVR included lower BMI (26.0 kg/m² [IQR 24.0 kg/m² to 29.1 kg/m²] versus 29.1 kg/m² [IQR 26.6 kg/m² to 32.0 kg/m²]; P=0.05), IL28B genotype CC (37% versus 12%; P=0.02) and cirrhosis (37% versus 60%; P=0.03). In a multivariate analysis, only fibrosis class (F0 to F2 versus F3 to F4; adjusted OR 0.34 [95% CI 0.12 to 0.99]; P=0.05) remained significantly associated with SVR. HIV status, a history of injection drug use and previous response to peg-IFN therapy did not predict SVR.

There have been few reports of the effectiveness of TVR-based therapy in HIV-coinfectd patients outside of clinical trials. In our study, the overall SVR was 67% in HCV-monoinfected patients and 62% in coinfectd patients. This is comparable with clinical trials, despite a higher percentage of patients with cirrhosis (45%) in our cohort (4-6). Lower BMI, IL28B CC genotype and degree of fibrosis were associated with increased probability of SVR, although in multivariate analysis, only degree of fibrosis remained a significant predictor of SVR. Additional negative predictors of SVR with TVR-based therapy included African American race and previous treatment response (13). We also demonstrated that HIV coinfection is not a negative predictor of SVR. This was consistent with trials involving second-generation DAAs such as ledipasvir and sofosbuvir. Data from patients with HCV mono-infection treated

TABLE 1
Comparison of baseline characteristics between hepatitis C virus (HCV)-monoinfected and HIV-HCV coinfecting patients

	All (n=103)	HCV monoinfected (n=90)	HCV-HIV coinfecting (n=13)	P*
Age at treatment onset, years, median (IQR)	56 (51–59)	56 (51–59)	53 (46–57)	0.20
Male sex	74 (72)	63 (70)	11 (85)	0.34
Race/ethnicity				
Caucasian	73 (86)	63 (88)	10 (77)	0.07
Previous injection drug use	31 (37)	23 (33)	8 (62)	0.05
Hemophilia	9 (10)	5 (7)	4 (31)	0.03
Post-liver transplant	7 (8)	7 (10)	0 (0)	0.59
Hepatitis B coinfection	3 (3)	3 (45)	0 (0)	1.00
Body mass index, kg/m², median (IQR)	26.8 (24.0–30.5)	27.1 (24.0–32.0)	25.1 (24.5–28.4)	0.22
Previous HCV treatment				
Naive	50 (53)	44 (54)	6 (46)	0.11
Relapse	28 (29)	26 (32)	2 (15)	
Null	12 (13)	9 (11)	3 (23)	
Partial	1 (1)	1 (1)	0 (0)	
Intolerant	4 (4)	2 (2)	2 (15)	
HCV genotype				
1a	48 (71)	42 (71)	6 (67)	1.00
Interleukin 28B genotype				
CC	18 (30)	16 (33)	2 (17)	0.58
CT	30 (50)	23 (48)	7 (58)	
TT	12 (20)	9 (19)	3 (25)	
FibroScan[†], median (IQR)	11.3 (7.3–17.3)	10.9 (7.3–17.3)	12.0 (8.4–15.7)	0.88
Fibrosis/cirrhosis				
F0–F1	20 (20)	18 (20)	2 (15)	0.30
F2	21 (21)	20 (22)	1 (8)	
F3	15 (15)	11 (12)	4 (31)	
F4/cirrhosis	46 (45)	40 (45)	6 (46)	
Baseline labs				
Hemoglobin, g/L, median (IQR)	151 (140–162)	152 (140–162)	14.8 (142–160)	0.89
Platelets, ×10 ⁹ /L, median (IQR)	165 (126–202)	169 (130–202)	141 (123–178)	0.43
Alanine aminotransferase, U/L, median (IQR)	72 (48–115)	72 (46–114)	66 (51–132)	0.85
Total bilirubin, µmol/L, median (IQR)	9 (7–13)	9 (6–13)	10 (7–16)	0.28
Albumin, µmol/L, median (IQR)	39 (37–41)	39 (37–41)	38 (36–41)	0.55
International normalized ratio, median (IQR)	1.0 (1.0–1.1)	1.0 (1.0–1.1)	1.0 (1.0–1.1)	0.36
Glomerular filtration rate ≤60 mL/min	6 (6)	5 (6)	1 (8)	0.59
HIV-related variables				
Undetectable HIV RNA	–	–	12 (92)	–
CD4 count, median (IQR)	–	–	490 (250–639)	–
HAART regimen				
Raltegravir	–	–	10 (77)	–
Atazanavir/ritonavir	–	–	2 (15)	–
Rilpivirine	–	–	1 (8)	–
Tenofovir	–	–	9 (69)	–
Emtricitabine	–	–	7 (54)	–
Lamivudine	–	–	5 (39)	–
Abacavir	–	–	4 (31)	–
Zidovudine	–	–	1 (8)	–
HAART change before treatment	–	–	11 (85)	–

Data presented as n (%) unless otherwise indicated. Bolded values indicate statistical significance (ie, $P < 0.05$). *HCV monoinfected versus HCV-HIV coinfecting. †Echosens, France. HAART Highly active antiretroviral therapy; IQR Interquartile range

with sofosbuvir/ledipasvir have demonstrated a rate of SVR >95% for all subgroups (14–16). A phase 3 study involving HIV-HCV coinfecting patients demonstrated similar rates of SVR (17). In fact, guidelines now suggest that HIV-HCV coinfecting patients should be treated the same as HCV-monoinfected patients (18,19).

HIV-coinfecting patients may experience a higher rate of adverse events associated with TVR-based therapy. In our cohort, coinfecting patients had similar rates of fatigue, changes in mood, rash, anorectal symptoms and thrombocytopenia, but were more likely to have infections and severe anemia. However, the rate of treatment

TABLE 2
Comparison of treatment outcomes between hepatitis C virus (HCV) monoinfected and HIV-HCV coinfecting patients

	All (n=103)	HCV monoinfected (n=90)	HCV-HIV coinfecting (n=13)	P*
Treatment outcomes				
Rapid virological response	63 (61)	51 (57)	12 (92)	0.02
Early virological response	81 (79)	68 (76)	13 (100)	0.07
End of treatment response	73 (71)	65 (72)	8 (62)	0.52
Sustained virological response	68 (66)	60 (67)	8 (62)	0.76
Sustained virological response subcategories				
Cirrhosis	25 (54)	21 (53)	4 (67)	0.67
Previous null responder	5 (42)	4 (44)	1 (33)	1.00
Post-liver transplant	–	4 (57)	–	–
Reason for treatment discontinuation				
Partial response	3 (3)	2 (2)	1 (8)	0.34
Null response	4 (4)	4 (4)	0 (0)	1.00
Relapse	15 (15)	12 (13)	3 (23)	0.40
Hepatic decompensation	5 (5)	4 (4)	1 (8)	0.50
Adverse event	20 (19)	18 (20)	2 (15)	1.00
Death	2 (2)	2 (2)	0 (0)	1.00
Lost to follow-up	2 (2)	1 (1)	1 (8)	0.24
Side effects				
Fatigue	53 (65)	44 (65)	9 (69)	1.00
Rash	55 (68)	47 (69)	8 (62)	0.75
Mood symptoms	34 (42)	27 (40)	7 (54)	0.37
Infection	14 (17)	8 (12)	6 (46)	<0.01
Anorectal symptoms	35 (43)	32 (47)	3 (23)	0.14
Anemia				
Hemoglobin nadir, g/L, median (interquartile range)	105 (89–118)	105 (90–117)	105 (74–120)	0.48
Hemoglobin $\leq$ 80 g/L	15 (15)	10 (11)	5 (38)	0.02
Red blood cell transfusion	9 (11)	6 (9)	3 (23)	0.15
Erythropoietin use	2 (2)	1 (1)	1 (8)	0.30
Thrombocytopenia				
Platelet nadir, g/L, median (interquartile range)	83 (53–113)	86 (54–131)	67 (48–93)	0.31
Platelets $\leq$ 50 $\times$ 10 ⁹ /L	24 (24)	20 (22)	4 (31)	0.50
Ribavirin dose reduction	46 (57)	41 (60)	5 (38)	0.22
Pegylated interferon dose reduction	10 (12)	4 (6)	6 (46)	<0.01

Data presented as n (%) unless otherwise indicated. Bolded values indicate statistical significance (ie, $P < 0.05$). *HCV monoinfected versus HCV-HIV coinfecting

discontinuation related to adverse events did not differ from monoinfected patients. Therefore, TVR can be safely administered to coinfecting patients, provided there is close monitoring. Second-generation anti-HCV DAAs have an improved side effect profile and have significantly reduced the risk for treatment-associated adverse events (20). However, HCV-HIV coinfecting patients who receive anti-HCV therapy that includes RBV may require more frequent monitoring of complete blood count, given the propensity to develop severe anemia. TVR is a potent CYP 3A4 inhibitor and, therefore, another consideration among HIV-coinfecting patients is drug-drug interactions with antiretroviral therapy. The majority (85%) of our patients required a change in antiretroviral medication before initiation of TVR. Many of these patients were stable on their previous HIV regimen for many years before this change. The risk for drug-drug interactions with highly active antiretroviral therapy is less of a concern with second-generation DAAs for HCV; however, due to high cost, these newer agents may not be available in resource-limited countries and, hence, TVR may still be required for anti-HCV therapy in many regions.

One limitation of the present study was the relatively small sample size. Furthermore, IL28b and HCV genotype subtype was not

available for 42% (n=43) and 34% (n=35) of patients, respectively. Another possible limitation was selection bias – in that patients who were more likely to adhere to a complicated regimen and tolerate side effects were offered TVR-based therapy. Treatment may have been deferred (ie, until the second-generation DAAs were available) for more challenging-to-treat patients. However, a key strength of our study was that it was inclusive of all patients treated with TVR. Most clinical trials and observational studies specifically excluded HIV-coinfecting patients, post-liver transplant recipients, patients with decompensated liver disease and hepatitis B virus-coinfecting patients. Therefore, our results are generalizable to a real world clinical setting.

In summary, we present the first study to our knowledge involving HCV-HIV coinfecting patients treated with TVR-based therapy in Canada. We found coinfecting patients had comparable rates of SVR to monoinfected patients, albeit with an added risk for certain adverse events, namely infections and severe anemia. With the approval of second-generation DAAs, HIV-coinfecting patients in Canada now have access to more potent and effective anti-HCV therapy with an improved side effect profile and shortened treatment duration. These treatment advances will ultimately reduce the burden of HCV-related morbidity and mortality in individuals living with HIV.

ACKNOWLEDGEMENTS: The authors acknowledge all the staff at the Calgary Liver Unit and the Southern Alberta Clinic. They also thank Dr Mel Krajden at the British Columbia Centre for Disease Control for IL28B genotype testing.

Conar R O'Neil MD
Department of Internal Medicine,
University of Calgary Cumming School of Medicine,
Calgary, Alberta

Jack XQ Pang MSc, Samuel S Lee MD FRCPC,
Mark G Swain MD MSc FRCPC, Kelly W Burak MD MSc FRCPC,
Patricia Klein BN, Robert P Myers MD MSc FRCPC
Calgary Liver Unit, Division of Gastroenterology and Hepatology,
University of Calgary Cumming School of Medicine,
Calgary, Alberta

Jeff Kapler BScPharm
Southern Alberta Clinic, Calgary, Alberta

Michael J Gill MB ChB MSc FRCPC FACP
Southern Alberta Clinic; Department of Microbiology,
Immunology and Infectious Diseases,
University of Calgary Cumming School of Medicine,
Calgary, Alberta

Martin Labrie MD CCFP
Southern Alberta Clinic; Department of Family Medicine,
University of Calgary Cumming School of Medicine
Calgary, Alberta

Carla S Coffin MD MSc FRCPC
Calgary Liver Unit, Division of Gastroenterology and Hepatology,
University of Calgary Cumming School of Medicine;
Southern Alberta Clinic; Department of Microbiology,
Immunology and Infectious Diseases, University of Calgary Cumming
School of Medicine, Calgary, Alberta

REFERENCES

1. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. *Arch Intern Med* 2006;166:1632-41.
2. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. *N Engl J Med* 2004;351:451-9.
3. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med* 2004;351:438-50.
4. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011;364:2417-28.
5. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med* 2011;365:1014-24.
6. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011;364:2405-16.
7. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: A randomized trial. *Ann Intern Med* 2013;159:86-96.
8. Montes M, Nelson M, Girard PM, et al. Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): Sustained virologic response at 12 weeks final analysis. *J Int AIDS Soc* 2014;17(4 Suppl 3):19626.
9. Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: Consensus guidelines from the Canadian Association for the Study of the Liver. *Can J Gastroenterol* 2012;26:359-75.
10. Hull M, Klein M, Shafran S, et al. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. *Can J Infect Dis Med Microbiol* 2013;24:217-38.
11. Pang JX, Zimmer S, Niu S, et al. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. *PLoS One* 2014;9:e95776.
12. Faisal N, Yoshida EM, Bilodeau M, et al. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: A multicenter experience. *Ann Hepatol* 2014;13:525-32.
13. Martel-Laferrriere V, Brinkley S, Bichoupan K, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. *HIV Med* 2014;15:108-15.
14. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med* 2014;370:1889-98.
15. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med* 2014;370:1483-93.
16. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. *N Engl J Med* 2014;370:1879-88.
17. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfecting with HIV-1. *N Engl J Med* 2015;373:705-13.
18. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. *Can J Gastroenterol Hepatol* 2015;29:19-34.
19. Hull M, Shafran S, Tseng A, Giguere P, Klein MB, Cooper C. CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfecting adults. *Can J Infect Dis Med Microbiol* 2014;25:311-20.
20. O'Neil CR, Coffin CS. Management of hepatitis C virus and human immunodeficiency virus coinfection. *Minerva Gastroenterol Dietol* 2014;60:165-175.